BenQ Launches Flagship ScreenBar® Halo 2 to Redefine Eye Comfort for Professionals Working in the Dark
PLANO, Texas, June 3, 2025 /CNW/ -- BenQ, the pioneer of monitor lighting solutions, today launched the ScreenBar® Halo 2, its next-generation flagship monitor light engineered to deliver optimal eye comfort for professionals working in dim environments. Developed over four years, the ScreenBar® Halo 2 enhances workspace lighting through a powerful dual-light design that provides full front and rear illumination.
Building on the success of its predecessor, the ScreenBar® Halo 2 introduces a Tri-zone Backlight Design that expands coverage by 423%, reducing contrast between the monitor and its surroundings to ease visual fatigue. The front light features BenQ's ASYM-Light™, an asymmetrical optical design with an 18-degree cut-off angle that eliminates screen glare and prevents direct light from reaching the eyes.
The product's development was informed by a study conducted in collaboration with National Taiwan University of Science and Technology, which found that maintaining balanced ambient light around a screen significantly improves eye comfort. Backed by ANSI standards, the optimal luminance ratio of no more than 3:1 between the screen and its surroundings is a core element of the ScreenBar® Halo 2's design.
"We know professionals demand precision in lighting," said JC Pan, Chief Product Designer at BenQ Smart Lighting. "That's why we've revamped the control knob, making it easy to adjust brightness (0–100%) and color temperature (2700K–6500K) on an anti-fingerprint coated panel—ideal for tasks like color grading or video editing."
The mounting system also received a complete redesign. Inspired by the gravity-based mechanism of the ScreenBar Pro, the new zinc-alloy clamp supports a wide variety of monitors, from ultra-thin to curved, without causing damage. "It rests gently on the screen instead of clipping on, making it far more screen-friendly," said Judy Yang, lead mechanical engineer.
The ScreenBar® Halo 2 comes packed with smart features, including auto-dimming, auto on/off, and memory settings for personalized use. Co-designed with MINIMAL Design, founded by former Nike Global Creative Director Scott Wilson, it features a sleek metallic finish that complements any professional setup.
To celebrate the launch, BenQ is giving away 50 free units of the ScreenBar® Halo 2 across different regions. To enter, users simply need to complete a short questionnaire about their workspace habits. The giveaway is part of the #ElevatewithHalo campaign, where professionals will share how the product enhances their workflow and comfort.
#ElevatewithHalo runs from June 3 to June 20, 2025.Learn more: https://www.benq.com/en-us/campaign/elevate-with-halo.html
To learn more about BenQ monitor lighting series, please visit: https://www.benq.com/en-us/lighting/monitor-light.html
Since introducing the world's first monitor light bar in 2017, BenQ Smart Lighting has led innovation in professional lighting. With a mission to improve eye comfort and productivity, BenQ delivers intelligent, user-centric solutions for modern workspaces.
Media Contact:Jensen SM ChimProduct Manager, BenQ Smart LightingEmail: Jensen.SM.Chim@BenQ.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/benq-launches-flagship-screenbar-halo-2-to-redefine-eye-comfort-for-professionals-working-in-the-dark-302472271.html
SOURCE BenQ
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/03/c8807.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Simulations Plus Releases ADMET Predictor® 13
Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment RESEARCH TRIANGLE PARK, N.C., June 05, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. "ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space," said David Miller, Vice President of Cheminformatics of Simulations Plus. "Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world." Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27 minutes ago
- Business Wire
Simulations Plus Releases ADMET Predictor® 13
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. 'ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space,' said David Miller, Vice President of Cheminformatics of Simulations Plus. 'Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world.' Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
Yahoo
31 minutes ago
- Yahoo
Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal
SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughput, high-quality protein biomarker discovery services using Olink's leading proteomics platforms. This multi-site certification validates Novogene's capabilities to execute Olink® workflows with exceptional precision, consistency, and scalability across global labs—enabling advanced translational research and precision medicine for pharmaceutical, biotech, and academic partners. Novogene has broadened its suite of high-plex proteomics, with the addition of Olink® Reveal. Olink® Reveal enables the quantification of ~1,000 curated human proteins, including 537 inflammation markers, spanning 96% of immune response pathways and 64% of all Reactome pathways. The assay features validated, biologically relevant content enriched with cis-pQTLs—ideal for proteogenomic applications—allowing researchers to both broadly screen the proteome and deeply investigate inflammation biology. "Being certified as an Olink® CSP across multiple Novogene labs underscores our commitment to delivering high-quality, globally harmonized data. With Olink® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions." said Justin Lee, Novogene VP of Global Marketing. "We are extremely excited to see Olink® proteomics solutions being adopted by Novogene, a global provider of multi-omics solutions," said Andrea Ballagi, Olink VP of Sales and Marketing. "As part of a worldwide network of Olink® Certified Service Providers, Novogene is well-positioned to enable scientists around the world to advance biomarker research and contribute to a healthier, cleaner and safer world". As part of the Olink® global CSP network, Novogene is committed to deliver reproducible, high-quality data to empower the exploration of disease mechanisms, therapeutic targets, and novel biomarkers. About NovogeneNovogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation. CONTACT: Novogene AMEA (APAC, Middle-East & Africa)marketing_amea@ View original content: SOURCE Novogene
